Competing interests
FMS
ONCOLOGY, FMS
SPN reports consultant or advisory role with Immmunocore and Pierre-Fabre and travel grants from PharmaMar. MSC receives consulting fees from Amgen, Bristol-Myers Squibb, Eisai, Ideaya, Merck Sharp and Dohme, Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, and Roche and honoraria for lectures from Bristol-Myers Squibb, Merck Sharp and Dohme, and Novartis. VB receives institutional financial support for clinical trials from Abbvie, ACEO, Adaptaimmune, Amcure, Amgen, AstraZeneca, BMS Cytomx, GSK, Genentech/Roche, H3, Incyte, Janssen, Kura, Lilly, Loxo, Nektar, Macrogenics, Menarini, Merck, Merus, Nanobiotix, Novartis, Pfizer, PharmaMar, Principia, PUMA, Sanofi, Taiho, Tesaro, BeiGene, Transgene, Takeda, Incyte, Innovio, MSD, PsiOxus, Seattle Genetics, Mersana, Daiichi, Nektar, Astellas, ORCA, Boston Therapeutics, Dynavax, DebioPharm, Boehringer Ingelheim, Regeneron, Millennium, Synthon, Spectrum, Rigontec, and Zenith, reports consultant or advisory role with Puma Biotechnology, Ideaya Biosciences, Loxo Therapeutics, CytomX Therapeutics, Guidepoint, and Oncoart, receives honoraria from Eli Lilly and MSD, and receives support for attending meetings and/or travel from Bayer. DL receives consulting fees from MSD, Roche, Gilead, Lilly, Novartis, Pfizer, Pharma4D, and AstraZeneca, honoraria from MSD, Roche, Gilead, Lilly, Novartis, Pfizer, and AstraZeneca, and support for attending meetings and/or travel from MSD, Gilead, Novartis, Pfizer, and AstraZeneca. EC receives honoraria from HM Hospitales Group, reports consulting or advisory role from Nanobiotix, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, Roche/Genentech, Amcure, TargImmune Therapeutics, Servier, Bristol-Myers Squibb, PharmaMar, Alkermes, Amunix, Adcendo, Anaveon, AstraZeneca/MedImmune, BeiGene, Chugai Pharma, MonTa, MedSIR, MSD Oncology, Nouscom, Novartis, OncoDNA, Sanofi, Syneos Health, T-Knife, and Boehringer Ingelheim, receives research funding from BeiGene, START, and Achilles, owns stock from START and Oncoart Associated. RDC receives consulting fees from Alkermes, BMS, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento, and TriSalus, receives honoraria for lectures from PER and Oncology Data Advisor, is on advisory board of Alkermes, BMS, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento, and TriSalus, and owns stock from Rgenix, Aura, and Chimeron. MN receives honoraria for lectures and for leading expert meetings from BMS, MSD, Roche, Pierre-Fabre, and Roche. EK reports consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, and Pierre Fabre (paid to the institution) and received research grants not related to this paper from Bristol Myers Squibb and Pierre Fabre. AF, HEB, JGM, XZ, MDS, TR, and PYR are employees of Novartis, XZ and PYR have a pending US patent application, and HEB, JGM, XZ, MDS, TR, and PYR own stock from Novartis. FMS and JJP declare no competing interests.